MASSACHUSETTS GENERAL HOSPITAL

Tonix Pharmaceuticals has dosed the first patient in the FOCUS study, evaluating intranasal potentiated oxytocin products TNX-1900 and TNX-2900 for arginine-vasopressin deficiency (AVP-D), a rare endocrine disorder formerly known as central diabetes insipidus.

Tonix Pharmaceuticals presented Phase 1 safety and biomarker data for TNX-1500, a third-generation Fc-modified anti-CD40L monoclonal antibody designed to prevent organ transplant rejection.

Mass General Brigham researchers demonstrated that a wearable heart rate variability biofeedback device significantly reduced substance cravings and use in early recovery patients.

SELLAS Life Sciences will host a virtual R&D Day on October 29, 2025, featuring key opinion leaders discussing acute myeloid leukemia treatment advances and unmet medical needs.

Pritelivir demonstrated superior lesion healing rates compared to foscarnet in Phase 2 trial, with 93% vs. 57% of patients achieving healing within 28 days of treatment.

Bill Stewart, a 54-year-old New Hampshire man, successfully received a genetically engineered pig kidney transplant on June 14 and no longer requires dialysis after being discharged from Massachusetts General Hospital.

Treeline Biosciences has launched Phase 1 clinical trials for three oncology programs: TLN-121 (BCL6 degrader), TLN-372 (pan-KRAS inhibitor), and TLN-254 (EZH2 inhibitor) targeting lymphomas and solid tumors.

A custom-built antisense oligonucleotide drug targeting the CHCHD10 gene mutation has slowed ALS progression by more than half in Dr. Rakesh Parekh, marking the first treatment for this specific genetic variant.

Thryv Therapeutics will present compelling preclinical results for THRV-1268, a best-in-class SGK1 inhibitor, at the European Society of Cardiology Congress 2025 in Madrid.

A Phase I/II clinical trial at UMass Chan Medical School demonstrated biochemical correction of GM2 gangliosidosis using dual vector gene therapy with minimal adverse reactions.